US · PRAX · BIOTECHNOLOGY
Praxis Precision Medicines, Inc. (PRAX) intrinsic value and stock valuation
$300.43as of 2026-11-21 · Mkt cap 8.9B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Praxis Precision Medicines, Inc. DCF and intrinsic value
InvestorsCraft values PRAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRAX’s statements →
Praxis Precision Medicines, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $8.55M | $2.45M | $0.00 | $0.00 |
| Operating income | -$-326.2M | -$-200.16M | -$-126.37M | -$-214.99M | -$-167.33M |
| Net income | -$-303.27M | -$-182.82M | -$-123.28M | -$-214.03M | -$-167.06M |
| EPSd | -$-13.48M | -$-10.21M | -$-18.71M | -$-69.72M | -$-59.03M |
| Operating cash flow | -$-249.07M | -$-131.76M | -$-111.14M | -$-185.04M | -$-124.55M |
| Capital expenditure | -$-60K | $0.00 | -$-50K | -$-440K | -$-1.05M |
| Free cash flow | -$-249.12M | -$-131.76M | -$-111.19M | -$-185.49M | -$-125.6M |
| Total assets | $937.9M | $483.1M | $88M | $115.1M | $292.8M |
| Total debt | $110K | $1.37M | $2.5M | $3.5M | $4.31M |
| Net debt | -$-357.22M | -$-214M | -$-78.81M | -$-58.12M | -$-134.39M |
| Total equity | $878.1M | $445.5M | $69.7M | $76.1M | $250.8M |
| Cash and short-term investments | $599.3M | $392.6M | $81.3M | $100.5M | $275.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $8.55M | $2.45M | $0.00 | $0.00 |
| Cost of revenue | $140K | $152.4M | $86.8M | $154.4M | $0.00 |
| Gross profit | -$-140K | -$-143.86M | -$-84.32M | -$-154.44M | $0.00 |
| Research and development expenses | $267.1M | $152.4M | $86.8M | $155M | $120.3M |
| Selling, general and administrative expenses | $59.1M | $56.3M | $42.1M | $59.6M | $47.1M |
| Other expenses | $0.00 | -$-152.41M | -$-86.77M | -$-154.04M | $0.00 |
| Operating expenses | $326.1M | $56.3M | $42.1M | $60.6M | $167.3M |
| Cost and expenses | $326.2M | $208.7M | $128.8M | $215M | $167.3M |
| Interest income | $22.9M | $17.4M | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $140K | $360K | $430K | $420K | $180K |
| Ebitda | -$-303.13M | -$-182.46M | -$-122.84M | -$-213.57M | -$-166.88M |
| Operating income | -$-326.2M | -$-200.16M | -$-126.37M | -$-214.99M | -$-167.33M |
| Total other income/expenses, net | $22.9M | $17.4M | $3.1M | $960K | $270K |
| Income before tax | -$-303.27M | -$-182.82M | -$-123.28M | -$-214.03M | -$-167.06M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-303.27M | -$-182.82M | -$-123.28M | -$-214.03M | -$-167.06M |
| Weighted average shares outstanding | $22.5M | $17.9M | $6.59M | $3.07M | $2.83M |
| Weighted average diluted shares outstanding | $22.5M | $17.9M | $6.59M | $3.07M | $2.83M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $599.3M | $392.6M | $81.3M | $100.5M | $275.9M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $610.9M | $404.4M | $84.9M | $110.8M | $287.4M |
| Property, plant and equipment, net | $240K | $1.36M | $2.65M | $3.87M | $4.87M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $77M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $327M | $78.7M | $3.07M | $4.29M | $5.34M |
| Total assets | $937.9M | $483.1M | $88M | $115.1M | $292.8M |
| Accounts payable | $24.6M | $12.5M | $5.82M | $14.7M | $10.8M |
| Short-term debt | $110K | $1.26M | $1.13M | $1M | $810K |
| Deferred revenue | $0.00 | $0.00 | $1.39M | $2.82M | $0.00 |
| Total current liabilities | $59.8M | $37.6M | $15.8M | $34.3M | $38.4M |
| Long-term debt | $0.00 | $110K | $1.37M | $2.5M | $3.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $1.16M | $2.18M | $0.00 |
| Total non-current liabilities | $0.00 | $110K | $2.53M | $4.68M | $3.5M |
| Capital lease obligations | $110K | $1.37M | $2.5M | $3.5M | $4.31M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39M | $41.9M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.14B | -$-836.74M | -$-653.92M | -$-530.64M | -$-316.62M |
| Accumulated other comprehensive income (loss) | $560K | $650K | $0.00 | -$-170K | -$-180K |
| Total equity | $878.1M | $445.5M | $69.7M | $76.1M | $250.8M |
| Total investments | $242M | $254.2M | $0.00 | $38.9M | $137.2M |
| Total debt | $110K | $1.37M | $2.5M | $3.5M | $4.31M |
| Net debt | -$-357.22M | -$-214M | -$-78.81M | -$-58.12M | -$-134.39M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-303.27M | -$-182.82M | -$-123.28M | -$-214.03M | -$-167.06M |
| Depreciation and amortization | -$-3.45M | $360K | $430K | $420K | $180K |
| Stock-based compensation | $33.9M | $41.4M | $24.9M | $28.6M | $22.7M |
| Change in working capital | $22.7M | $10.9M | -$-13.03M | -$-1.78M | $16.1M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $12.1M | $6.71M | -$-8.86M | $3.89M | $7.27M |
| Net cash provided by operating activities | -$-249.07M | -$-131.76M | -$-111.14M | -$-185.04M | -$-124.55M |
| Investments in property, plant and equipment | -$-60K | $0.00 | -$-50K | -$-440K | -$-1.05M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-97.33M | $139.5M |
| Net cash used for investing activities | -$-311.15M | -$-248.49M | $39M | $96.9M | -$-140.52M |
| Common stock issued | $704.3M | $512M | $91.6M | $9.56M | $105.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $702.2M | $514.3M | $91.9M | $10.5M | $107.6M |
| Net change in cash | $142M | $134.1M | $19.7M | -$-77.69M | -$-157.49M |
| Cash at end of period | $357.8M | $215.8M | $81.7M | $62M | $139.7M |
| Operating cash flow | -$-249.07M | -$-131.76M | -$-111.14M | -$-185.04M | -$-124.55M |
| Capital expenditure | -$-60K | $0.00 | -$-50K | -$-440K | -$-1.05M |
| Free cash flow | -$-249.12M | -$-131.76M | -$-111.19M | -$-185.49M | -$-125.6M |
Line items
Line items
Line items
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
- CEO
- Marcio Silva De'Souza
- Employees
- 168
- Beta
- 2.76
Explore
Frequently asked questions
What is the intrinsic value of Praxis Precision Medicines, Inc. (PRAX)?
InvestorsCraft does not currently publish an intrinsic value for PRAX. How the IC value is calculated.
Is PRAX undervalued?
InvestorsCraft does not publish an undervaluation signal for PRAX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.